Effects of Tenofovir on the Single-Dose Pharmacokinetics of Intravenous Morinidazole in Healthy Chinese Subjects
Open Access
- 21 April 2020
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 64 (5)
- https://doi.org/10.1128/aac.02067-19
Abstract
The effects of multiple-dose administration of tenofovir disoproxil fumarate (TDF) on the pharmacokinetics of morinidazole (MOR) were compared in healthy subjects. MOR exposure was similar, with an area under the curve from 0 h to infinity (AUC0-∞) treatment ratio for MOR+TDF/MOR of 1.01 (90% confidence interval, 0.97 to 1.06). No relevant differences were observed regarding plasma exposure of metabolites. Renal clearances of MOR and its metabolites were not affected by TDF. No unexpected safety or tolerability issues were observed.Funding Information
- National Natural Science Foundation of China (81703615)
- NSF | Foundation for Innovative Research Groups of the National Natural Science Foundation of China (2017ZX09303002)
This publication has 14 references indexed in Scilit:
- Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic ToxinsDrug Metabolism and Disposition, 2017
- Efficacy and safety of morinidazole in pelvic inflammatory disease: results of a multicenter, double-blind, randomized trialEuropean Journal of Clinical Microbiology & Infectious Diseases, 2017
- Effects of Rifampin and Ketoconazole on Pharmacokinetics of Morinidazole in Healthy Chinese SubjectsAntimicrobial Agents and Chemotherapy, 2014
- Effects of Renal Impairment on the Pharmacokinetics of Morinidazole: Uptake Transporter-Mediated Renal Clearance of the Conjugated MetabolitesAntimicrobial Agents and Chemotherapy, 2014
- Metabolism and Pharmacokinetics of Morinidazole in Humans: Identification of Diastereoisomeric Morpholine N+-Glucuronides Catalyzed by UDP Glucuronosyltransferase 1A9Drug Metabolism and Disposition, 2011
- Lack of Interaction Between the HIV Integrase Inhibitor S/GSK1349572 and Tenofovir in Healthy SubjectsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Lack of a Significant Drug Interaction between Raltegravir and TenofovirAntimicrobial Agents and Chemotherapy, 2008
- Tenofovir Disoproxil FumarateClinical Pharmacokinetics, 2004
- Affinity of Drugs to the Different Renal Transporters for Organic Anions and Organic CationsPharmaceutical Biotechnology, 2002